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Murine roseolovirus does not accelerate
amyloid-β pathology and human
roseoloviruses are not over-represented in
Alzheimer disease brains
Tarin M. Bigley1†, Monica Xiong2,3,4†, Muhammad Ali6, Yun Chen2,3,5, Chao Wang2, Javier Remolina Serrano2,
Abdallah Eteleeb6,7, Oscar Harari2,6,7, Liping Yang8, Swapneel J. Patel8, Carlos Cruchaga2,6,7,
Wayne M. Yokoyama8* and David M. Holtzman2*

Abstract
Background: The role of viral infection in Alzheimer Disease (AD) pathogenesis is an area of great interest in recent
years. Several studies have suggested an association between the human roseoloviruses, HHV-6 and HHV-7, and AD.
Amyloid-β (Aβ) plaques are a hallmark neuropathological finding of AD and were recently proposed to have an
antimicrobial function in response to infection. Identifying a causative and mechanistic role of human
roseoloviruses in AD has been confounded by limitations in performing in vivo studies. Recent -omics based
approaches have demonstrated conflicting associations between human roseoloviruses and AD. Murine
roseolovirus (MRV) is a natural murine pathogen that is highly-related to the human roseoloviruses, providing an
opportunity to perform well-controlled studies of the impact of roseolovirus on Aβ deposition.
Methods: We utilized the 5XFAD mouse model to test whether MRV induces Aβ deposition in vivo. We also
evaluated viral load and neuropathogenesis of MRV infection. To evaluate Aβ interaction with MRV, we performed
electron microscopy. RNA-sequencing of a cohort of AD brains compared to control was used to investigate the
association between human roseolovirus and AD.
Results: We found that 5XFAD mice were susceptible to MRV infection and developed neuroinflammation.
Moreover, we demonstrated that Aβ interacts with viral particles in vitro and, subsequent to this interaction, can
disrupt infection. Despite this, neither peripheral nor brain infection with MRV increased or accelerated Aβ plaque
formation. Moreover, −omics based approaches have demonstrated conflicting associations between human
roseoloviruses and AD. Our RNA-sequencing analysis of a cohort of AD brains compared to controls did not show
an association between roseolovirus infection and AD.
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Conclusion: Although MRV does infect the brain and cause transient neuroinflammation, our data do not support
a role for murine or human roseoloviruses in the development of Aβ plaque formation and AD.
Keywords: Alzheimer’s disease, Human roseolovirus, Murine roseolovirus, Amyloid-beta, Neuroinflammation

Background
In the past decades, major strides have been made to uncover the heterogeneous factors that contribute to the
etiology of Alzheimer Disease (AD). Recent advancements in biomarker studies predict that amyloid-β (Aβ)
plaques begin to aggregate in the brains of AD patients
15–20 years before the onset of cognitive symptoms. Aβ
accumulation triggers a local inflammatory response in
the central nervous system (CNS) and promotes subsequent intracellular tau accumulation in the neocortex
[1]. However, the initial events that drive Aβ seeding remain under debate and recently, pathogens have been
raised as contributing factors. Although the mechanistic
contributions of pathogens are unclear, multiple pathogens have been associated with AD. Recent studies have
suggested that Aβ may act as an antimicrobial peptide
that binds to pathogens and limits their entry [2–6]. In
these studies, Aβ seeding was proposed to accelerate as
part of an immune response to infection, and repeated
or chronic infection results in persistent inflammation
and Aβ accumulation.
Herpesviruses have been considered in the pathogenesis of AD because they are ubiquitous in the population, cause chronic infections that periodically reactivate,
and several herpesviruses, including herpes simplex viruses (HSV-1 and HSV-2), cytomegalovirus, EpsteinBarr virus, and the human roseoloviruses infect the CNS
and cause neuroinflammation [7, 8]. Indeed, the herpesviruses have been associated with AD [9–14]. The human roseoloviruses, HHV-6A, HHV-6B and HHV-7,
have received particular attention given their link with
CNS diseases, such as multiple sclerosis and encephalitis
[15, 16]. Moreover, there are reports of increased HHV6 DNA in AD brains compared to non-AD controls
[17], decreased HHV-6 IgG titers in the blood of AD patients compared to controls [6], and a human leukocyte
antigen subtype associated with increased susceptibility
to HHV-6A infection that was suggested to be an AD
genetic risk factor [18]. A recent publication by Readhead, et al. utilizing transcriptomic, genomic and proteomic analysis of several brain banks suggested a link
between human roseoloviruses, specifically HHV-6A and
HHV-7, and AD [19]. Furthermore, another study observed Aβ aggregating around HHV-6 in vitro [5]. However, a reanalysis of the study published by Readhead,
et al. using a different statistical methodology [20], as
well as an additional cohort study of brain banks using
transcriptomics and digital droplet PCR [14], both

suggested a lack of association between human roseoloviruses and AD.
Establishing a causal link between human roseoloviruses and AD is hindered by the high prevalence and
chronicity of infection [21, 22]. The beta-herpesviruses
demonstrate species-specific tropism, therefore in vivo
studies of human roseoloviruses have been limited to
immunodeficient humanized mice or transgenic mice
expressing the receptor for HHV-6A, CD46 [23–25].
While these are useful models to study human roseoloviruses, there are clear restraints. The humanized mouse
models are immunodeficient and infection is limited to
transferred human cells, whereas the CD46 transgenic
mouse models utilize intracranial infection and are limited to HHV-6A infection [23–25]. On the other hand,
murine roseolovirus (MRV) is genetically and morphologically highly-related to the human roseoloviruses and
likely has high prevalence in wild mouse populations
[26–28]. Neonatal infection with MRV results in transient failure to gain weight, thymic atrophy and CD4+ T
cell depletion [26, 29]. We have previously shown that
viral DNA was observed in the CNS after neonatal infection, although viral replication was not evaluated [26].
Furthermore, MRV DNA appeared to persist at low
levels into adulthood, suggesting it establishes life-long
latency similar to other herpesviruses.
Given the similarities of MRV to human roseoloviruses
and its ability to infect the CNS, herein we investigated
the impact of MRV on Aβ accumulation in vivo using
the 5XFAD mouse model that overexpresses human
APP and PSEN1 transgenes with five AD-linked mutations [30]. We demonstrated that 5XFAD mice are susceptible to MRV infection and observed expression of
late viral transcripts in the brain during acute infection,
suggesting active viral replication. Additionally, we detected inflammation in the brain after peripheral and
direct central nervous system (CNS) infection. Furthermore, Aβ interacts with MRV particles in vitro and, subsequent to this interaction, can disrupt infection. Despite
the presence of MRV in the brains of 5XFAD mice, we
did not detect increased accumulation of Aβ aggregates.
Moreover, when we used RNA-sequencing (RNAseq) to
evaluate a cohort of brains from Knight-ADRC research
participants who either were cognitively unimpaired
without AD or who had dementia due to AD at time of
death, we found there was no association between HHV6 infection frequency and AD. Taken together, our data
demonstrate that although MRV infects the brain and
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induces both an acute peripheral and central inflammatory response, MRV does not increase Aβ aggregation in
the brains of 5XFAD mice. Similarly, we found no association of HHV-6 RNA prevalence in AD human brains.

Methods
Animals

5XFAD (B6SJL-Tg (APPSwFlLon,PSEN1*M146L*L286V)
6799Vas/Mmjax) and B6SJLF1/J mice were purchased
from Jackson Laboratories. BALB/c mice were purchased
from Charles River Laboratories. Mice were bred in
house under pathogen-free conditions. Mice that were
MRV-infected were housed in separate cages from
mock-infected mice to avoid horizontal transmission.
For all neonatal infections, male and female mice were
infected and included in the experiments (sex ratio overall was ~ 50%). For infection of adult mice, female mice
were used for all studies. These studies were conducted
in accordance with institutional ethics guidelines in
place through institutional animal care and use committee (IACUC) protocols approved by the Animal Studies
Committee of Washington University in St. Louis.
Virus stock and infection

MRV stocks were prepared from in vivo passaging in
BALB/c mice as described previously [26]. For peripheral
infection, mice received intraperitoneal (i.p.) inoculation
using a 30-guage needle with 50 μL of a 1:5 dilution of
viral stock in serum-free DMEM for a dose of ~ 2 × 107
MRV genome copies. Mock infection was performed
similarly with 50 μL of serum-free DMEM.
For intracranial intrahippocampal injections, virus
stock was semi-purified through a sorbitol cushion as
described previously [31, 32], with several modifications.
Briefly, MRV virus stocks were prepared from minced
thymus. Cells were pelleted by centrifugation, then were
lysed using a cup horn sonicator. Large cellular debris
was pelleted by centrifugation and supernatant was removed and layered onto a 20% sorbitol cushion (20% dsorbitol, 50 mM Tris-HCl, pH 7.2, 1 mM MgCl2) at
55,000×g for 1 h using an ultracentrifuge. The remaining
pellet was resuspended in 1% fetal bovine serum (FBS)
in DMEM or PBS. For intracranial infection with semipurified MRV stocks in 1% (FBS), six-week-old 5XFAD
received bilateral, intrahippocampal injections of MRV
with a 5 μL Hamilton syringe with a 30-gauge needle attached to a Kopf stereotaxic instrument (4 × 106 MRV
genome copies; 2 μL/site; AP: -2.0, ML: + 1.6/− 1.6, DV:
− 2.0; 0.15 μL/min infusion rate). The needle was left undisturbed for 5 additional minutes after the injection before withdrawal. All mice were sacrificed 72 h post
infection. To evaluate the impact of Aβ on infection,
semi-purified viral stock in PBS was incubated with
DMSO control or oligomeric-Aβ42 at a concentration of
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10 μM for 2 h, then diluted 1:5 in PBS and 50 μL was
injected intraperitoneally into postnatal day 0 (P0)
BALB/c mice.
Nanogold-labeled Aβ sample preparation

Human Aβ42 peptides (Cat#: 107761–42-2, GenScript)
were resuspended with 1 mL of 1,1,1,3,3,3-Hexafluoro-2propanol (HFIP). HFIP was then evaporated in a chemical hood overnight to obtain dry monomeric Aβ42 layer
that was stored at − 20 °C in aliquots. On day of use, one
100 μg aliquot was dissolved with 5 μL of DMSO and diluted with sodium bicarbonate buffer (pH = 8.0) to make
10 μM monomeric Aβ42. Next, 10 nmol of Mono-SulfoN-Hydroxy-Succinimido- Nanogold® Labeling Reagent
(Cat#: 2025, Nanoprobes) was added to the solution and
incubated at RT overnight. Excess nanogold molecules
were removed via three-day dialysis in H2O with 3.5 kDa
cut-off tube at 4 °C. After dialysis, dry nanogold-labeled
or unlabeled Aβ42 was obtained after overnight speed
vacuum centrifugation at RT. The nanogold-labeled
Aβ42 was dissolved with 5 μL of DMSO and used for
preparation of monomeric, oligomeric Aβ42 and Aβ42 fibrils following a published protocol [33]. Briefly, oligomeric Aβ42 was formed using F12 media at 4 °C and
Aβ42 fibrils were formed in 10 mM HCl at 37 °C for at
least 24 h.
Negative staining transmission electron microscope (NSTEM) imaging

Before NS sample preparation, 10 μM of monomeric,
oligomeric and fibrillar nanogold-labeled Aβ42 was
mixed with purified MRV samples and incubated for 2 h.
Afterwards, all NS samples were vortexed and prepared
following standard uranyl formate negative staining
protocol. At least 50 TEM images containing viral particles per sample were obtained with JEOL JEM-1400 120
kV TEM with 80,000x magnitude. The quantification of
nanogold-labeled Aβ42 interaction with MRV particles
was conducted by a blinded reviewer scoring for nanogold negative or positive viral particles.
Tissue harvesting
Perfusion

Mice were anesthetized with Fatal-Plus (pentobarbital,
200 mg/kg, intraperitoneal) and transcardially perfused
for three minutes with chilled phosphate-buffered saline
(PBS) solution containing 0.3% heparin.
Brain extraction

Brains were hemisected: one hemisphere was dissected
for specific brain regions, flash-frozen on dry ice, and
stored at − 80 °C for biochemical and gene transcript
analyses; the other hemisphere was fixed in 4%
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paraformaldehyde for 24–48 h and cryoprotected in 30%
sucrose at 4 °C before sectioning for histology.

Two to three brain sections per mouse were averaged
for an individual biological replica.

Spleen and thymus collection

Tissue lysate extraction and ELISA
Brain homogenization

Spleen and thymus dissection was performed as described previously [29]. Briefly, for nucleic acid analysis
tissue was dissected and stored at − 80 °C or prepared
for flow cytometry as described below.
Histology and quantification
Sectioning

Hemibrains were sectioned coronally at 50 μm into six
series using a freezing, sliding microtome (Leica). Brain
slices were then stored at − 20 °C in cryoprotectant solution (0.2 M PBS, 15% sucrose, 33% ethylene glycol) until
use. All histological studies were conducted by staining
for two to three tissue slices from each mouse, separated
by 300 μm (bregma − 1.5, − 1.8, and − 2.1 mm or − 1.8,
and − 2.1 mm).
Immunostaining with DAB

Brain tissue staining was performed at room
temperature and on a shaker as previously described
[34]. Briefly, tissue sections were rinsed 3 times for 5
min each with Tris-buffered saline (TBS) and then
blocked for nonspecific binding with 3% milk in TBS
containing 0.25% Triton-X100 (TBS-X) for 30 min. Sections were then incubated at 4 °C overnight using primary antibodies (biotinylated anti-Aβ1–13 monoclonal
antibody HJ3.4B (produced in-house, 2 μg/mL) for Aβ,
mouse monoclonal anti-tau (gift from L. Binder, Northwestern University, 1:500) for Tau5, mouse monoclonal
anti-phospho-tau Ser202, Thr205 (Thermo Fisher Scientific, 1:500) for AT8 phosphorylated tau, and rabbit antiIba1 (Wako, 019–19,741, 1:5000) for microglia with biotinylated goat anti-rabbit IgG secondary antibody
(Thermo Fisher Scientific, 31,820, 1:1000). The following
day, tissue sections were rinsed 3 times for 5 min each
with TBS and incubated for 1 h in VectaStain Elite ABCHRP Kit, Peroxidase (Vector Laboratories, PK-6100) and
developed with DAB Eqv Peroxidase (HRP) Substrate
(Vector Laboratories, SK-4103) following the manufacturer protocols. Glass slides were cover-slipped with
cytoseal60 and allowed to air dry at room temperature
for at least 24 h. Stained brain sections were scanned
using a Nanozoomer 2.0-HT slide scanner (Hamamastu
Photonics) at 20X magnification, courtesy of the Hope
Center Alafi Neuroimaging Core.
Quantification

Images were quantified using Fiji software version 1.52v
(ImageJ). The percent area covered by immunostaining
was calculated by setting a single threshold per staining
experiment to traced cortical and hippocampal regions.

Mouse posterior cortices were first homogenized in
chilled PBS containing Complete Protease Inhibitor and
phosSTOP Phosphatase Inhibitor (“Soluble fraction”),
and then in 5 M guanidine-HCL buffer, pH 8.0 (“Insoluble fraction”) using magnetic beads (Next Advance,
Bullet Blender Storm 24).
Elisa

ELISAs were performed using 96-well, half-well plates
and concentrations were normalized to brain tissue
weight. All antibodies were made in-house: anti-Aβ35–40
HJ2 (capture antibody for Aβ40), anti-Aβ37–42 HJ7.4
(capture antibody for Aβ42), biotinylated anti-Aβ13–18
HJ5.1B (detection antibody for Aβ40 and Aβ42). Aβ sandwich ELISAs were performed as previously described
and concentrations were measured using Gen5 software
version 1.11 with Synergy 2 (BioTek) [35] Samples were
loaded in duplicates, averaged per mouse for an individual biological replicate.
Nucleic acid preparation and analysis

DNA was extracted from organs using the QIAamp
DNA Mini Kit (Qiagen) while RNA was extracted from
organs using the RNeasy Plus Kit (Qiagen) per manufacturer protocols. qPCR of DNA was performed using
TaqMan Universal Master Mix II (Applied Biosystems).
RNA was treated with DNase prior to being analyzed by
qPCR using TaqMan RNA-to CT 1-Step Kit (Applied
Biosystems). qPCR was analyzed on a StepOnePlus real
time PCR machine (Applied Biosystems). For MRV
ORF69 standard curves were created using a plasmid of
known base pairs in order to calculate copies/mL. For all
other, relative expression compared to Actb (beta-actin)
was calculated using ΔΔCt. Primers used included:
ORF69, Actb, IL-6, Iba1, ApoE, IL-1b, TREM2, GFAP.
Flow cytometry

Spleen and thymus were prepared for flow cytometry by
first crushing through a 70-μm cell strainer to obtain
single cell suspensions. Red blood cells were lysed then
cells were counted on a hemocytometer. Cells were
stained with fixable viability dye (eBioscience) then incubated with 2.4G hybridoma supernatant to block Fc receptors. Surface staining was performed with the
following fluorescent labeled antibodies: anti-CD3ε (1452C11), anti-CD4 (RM4–5), anti-CD8α (53–6.7), and
anti-CD44 (IM7) from Fisher Scientific, anti-CD19
(6D5), anti-NKp46 (29A1.4) and anti-CD62L (MEL-14)
from Biolegend, and anti-CD45.2 (104) from

Bigley et al. Molecular Neurodegeneration

(2022) 17:10

eBioscience. Flow cytometry was performed on a FACS
Canto (BD Biosciences) and analyzed using FlowJo v10
(TreeStar, Ashland, OR).
RNA-seq data pre-processing

Human parietal RNA-seq was generated from the
Charles F. and Joanne Knight Alzheimer’s Disease Research Center (Knight-ADRC) participants in two
batches using Ribo-zero 150 × 2 pair-end reads. A detailed description of the sample selection criteria, extracted brain tissues, and the pipeline used for preprocessing and analyzing the human bulk RNA-seq data
from this cohort is described elsewhere [36–39]. For this
study, we used a subset of samples that are either definitive AD or controls. Precisely, the subset of samples retrieved from the Knight-ADRC consisted of 350 samples
diagnosed with AD and 31 healthy controls. The obtained sequence files were in .bam format and already
mapped to GENCODE [40] annotated human reference
genome (GRCh38) using STAR software [41] in chimeric
read detection mode. Unaligned reads from these
aligned bam files were extracted using the “view -b -f 4”
command supported in the samtools suite (http://
samtools.sourceforge.net/). An unmapped BAM (uBAM)
was created including these reads by using the “RevertSam” command supported in the picard tool suite
(https://broadinstitute.github.io/picard/).
Viral screening using RNA-seq data

The unaligned RNA-seq reads (uBAM) files were
screened for a collection of microbes including HHV-6A
and HHV-6B by using the “PathSeq” tool developed by
the BROAD Institute (http://software.broadinstitute.org/
pathseq/), using the pre-built microbe reference files
(pathseq_microbe.fa.img). The total number of microbes
screened for observing their abundance in the selected
RNA-seq samples was 25,799 together with 118 human
viruses. We used the “PathSeqPipelineSpark” command
supported in the gatk tool suite (https://software.
broadinstitute.org/gatk/download/) for running the
“PathSeq” tool. The command was executed with default
parameters (https://gatkforums.broadinstitute.org/gatk/
discussion/10913/how-to-run-the-pathseq-pipeline) and
required pre-built references were downloaded from the
BROAD Institute (https://software.broadinstitute.org/
gatk/download/bundle). The virus detection scores per
individual sequence file output from the “PathSeq” tool
were then imported into R (https://cran.r-proiect.org/),
collated by cohort and virus types, visually inspected and
plotted using “ggplot2” R package (version 3.3.3) [42].
Statistical analysis of PathSeq results

Based on the number of samples that were positive and
negative for HHV-6A and HHV-6B, two vectors were

Page 5 of 17

produced containing normalized viral abundance scores,
and a non-parametric Wilcoxon Rank Sum test [43] was
performed to determine if there was any relationship between viral abundance and AD classification. The Wilcoxon Rank Sum test implementation in the base R
packages (version 3.5.2) [44] was used for this purpose.
Statistical analysis

Figures 1, 2, 3, 4, Supplementary Figs. 1, 2, 3: GraphPad
Prism 8.0.2 was used to perform statistical analyses. Data
are presented as means ± SD/SEM. No other statistical
comparisons were significant unless otherwise indicated.
For two groups: Statistical significance with normally distributed data was performed using a Student’s t-test
(two-tailed). For data with unequal standard deviations,
a t-test with Welch’s correction was performed. For
three or more groups: Gaussian distribution of data was
checked with the Anderson-Darling, D’Agostino and
Pearson, and Shapiro-Wilk normality tests. One-way
analysis of variance (ANOVA) followed by Tukey’s post
hoc test was used to determine statistical significance.
Asterisks represent P values as follows: * = P < 0.05, ** =
P < 0.01, *** = P < 0.001, *** = P < 0.0001.

Results
5XFAD mice are susceptible to MRV infection and
develop neuroinflammation

We previously demonstrated that neonatal, peripheral
MRV infection of BALB/c and C57BL/6 wild-type (WT)
mice resulted in MRV DNA in the CNS, depletion of
CD4 single positive (SP) and CD4CD8 double positive
(DP) thymocytes, CD4+ T cells in the periphery, and
peripheral inflammation as measured by an increase in
activated CD8+ T cells [26, 29]. To examine the consequences of MRV infection in 5XFAD mice, we first investigated whether MRV infects the brains of neonatal
5XFAD mice after peripheral infection using intraperitoneal (i.p.) injection (Fig. 1a). We evaluated MRV DNA in
the brains of 5XFAD mice compared to WT B6.SJL mice
at 7 days post infection (dpi) and found similar levels in
the cortex (Fig. 1b). Studies of herpesviruses have demonstrated that expression of late viral transcripts is correlated with viral replication [45]. We therefore utilized
expression of the putative late viral transcript, ORF69, as
a proxy of viral replication and found similar levels of
expression in 5XFAD and WT mice (Fig. 1c). We then
tested whether 5XFAD mice are susceptible to CD4+
thymocyte and peripheral CD4+ T cell depletion after
neonatal MRV infection. Indeed, we determined that
5XFAD mice develop depletion of CD4 SP and DP thymocytes as well as CD4+ T cell depletion and an increase in activated CD8+ T cells in the periphery (Fig.
1d, e). Finally, since our data suggested active MRV replication in the brain, we evaluated expression of multiple
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(See figure on previous page.)
Fig. 1 MRV infects the CNS and elicits a peripheral and central inflammatory response in 5XFAD mice. A Schematic of experimental paradigm. B,
C, Copies/mL of MRV DNA B and ORF69 RNA C in cortex of 5XFAD mice infected with mock or MRV 7 dpi (i.p.). D, E, Flow cytometry of absolute
number of CD45+CD19−NKp46− CD4+ or CD8+ thymocytes D and CD45+CD19−NKp46−CD3+ CD4+ or CD8+ T cells in the spleen E. F
Inflammatory gene expression changes in cortical tissue. *P < 0.05 between WT mock and 5XFAD MRV. DP: CD4+CD8+ double positive. DN:
CD4−CD8− double negative. ø represents below levels of detection. Dpi: days post infection. Data expressed as mean ± SD, one-way ANOVA with
Tukey’s post hoc test (two-sided) (b, c, d, e, f). P < 0.05. ns = not statistically significant. No other statistical comparisons are significant
unless indicated

inflammatory genes from the cortex of infected 5XFAD
and WT mice compared to uninfected WT mice. We
detected an increase in certain transcripts for microglia
(Iba1), disease-associated microglia (Trem2), diseaseassociated astrocytes (Gfap), and proinflammatory cytokines (Il6, Il-1b) (Fig. 1f) [46, 47].. Together, these data
demonstrate 5XFAD mice are equally susceptible to
MRV infection as WT mice, with functional peripheral
effects (T cell depletion) and viral replication in the
brain inducing increased expression of inflammatory
genes.
Aβ interacts with MRV particles in vitro and disrupts
infection in vivo

Studies proposing Aβ as an antimicrobial peptide are
predicated on the findings that, like other antimicrobial
peptides, Aβ interacts with pathogens to disrupt infection [2–4, 48]. Furthermore, Aβ has been demonstrated
to interact with herpesvirus particles, including HHV-6,
and inhibit HSV infection in vitro [3, 5]. We therefore
evaluated Aβ interactions with MRV. We generated
monomeric, oligomeric or fibrillar Aβ42 in a 10 μM suspension to differentiate which form of Aβ42 may interact
with MRV particles from purified viral stocks. We incubated viral particles with Aβ42 for 2 h, then used negative
staining transmission electron microscopy (NS-TEM) to
identify nanogold-labeled Aβ (> 1.4 nm). We found that
compared to PBS (Blank) and nanogold controls, all
forms of Aβ42 interacted with viral particles (Fig. 2a).
This was true for the majority of viral particles imaged,
although the percent of interaction was lowest for
monomeric Aβ42 (Fig. 2b). Interestingly, in general there
were no large aggregates of Aβ42 associated with viral
particles, nor was there direct interaction of Aβ42 fibrils
with viral particles even though the monomers/oligomers in the suspension did interact (Fig. 2a). Our data
does not differentiate if the nanogold-labeled Aβ interacting with MRV particles in the oligomeric and fibrillar
Aβ42 preparations was oligomeric or monomeric. Although we did not observe MRV interactions with large
Aβ42 aggregates as previously reported [5], these data
demonstrate that MRV does interact with certain forms
of Aβ42 in vitro.
We next evaluated whether Aβ42 has antimicrobial
properties against MRV. Inhibitory properties of

antimicrobial peptides, including Aβ42, were suggested
to be associated with Aβ oligomerization, which is the
preparation of Aβ42 we observed to have the highest percentage of interaction with MRV (Fig. 2b) [2, 5, 49–51].
We therefore tested the impact of oligomeric-Aβ42 on
MRV infection. Purified viral stock was incubated with
10 μM purified oligomeric-Aβ42 for 2 h, then BALB/c
mice were infected on postnatal day 0 (P0). We observed
that compared to control infection, oligomeric-Aβ42 incubation with MRV resulted in a marked reduction in
CD4 SP and DP depletion as well as a reduction in MRV
DNA in the thymus (Fig. 2c, d). These findings confirm
that Aβ42 interacts with MRV particles in vitro and then
subsequently disrupts MRV infection in vivo.
MRV infection does not increase cortical Aβ deposition of
5XFAD mice after peripheral infection

Human roseoloviruses infections typically occur in childhood and demonstrate high seroprevalence in adulthood
[21]. The impact and incidence of reinfection and frequency of reactivation of roseoloviruses is unknown, including for MRV. We therefore took several different
approaches to evaluate the influence of MRV infection
on the development of Aβ load. Because human roseoloviruses infections typically occur early in life, we performed neonatal i.p. infection of P0 neonatal 5XFAD
mice and assessed Aβ load at 6 months (Fig. S1a). While
we observed that the percentage of peripheral CD4+ T
cell per total T cells was decreased at 10 dpi (Fig. S1b)
similar to what we have published previously in other
mouse strains [26, 29], this effect was transient and no
longer present at 6 months post infection (mpi) (Fig.
S1c). Importantly, we did not observe a change in Aβ
plaque load in the cortex 6 mpi after neonatal MRV infection (Fig. S1d, e). Since accumulation of tau can also
be pathogenic, we evaluated immunostaining for total
tau and phosphorylated tau (p-tau) levels in mock and
MRV infected mice and did not observe increased levels
of either after MRV infection (Fig. S1f-i). One possibility
for the absence of an effect of MRV on Aβ plaque load
could be explained by a saturation effect of Aβ by 6
months of age. We therefore tested whether neonatal
MRV infection could accelerate the seeding of Aβ plaques in 6-week-old 5XFAD mice, a timepoint before the
formation of extracellular Aβ plaques (Fig. S1j) [30].
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Fig. 2 Aβ interacts with MRV in vitro and limits infection in vivo. A Interactions between purified MRV stock incubated for 2 h with PBS, Tris-nAu
control, monomeric Aβ42 (mAβ42), oligomeric Aβ42 (oAβ42), or fibrillar Aβ42 (fAβ42) labeled with nanogold. Blue arrowhead: Viral particle. Red
arrowhead: nanogold+ labeling. Green arrowhead: Fibrillar Aβ. A representative image with scale bar = 50 nm shown for each image with 5X
increased magnification inset (white box represents area of inset) in the bottom left of image for viral particles or right of image for fibril. B
Quantification of viral particles positive for nanogold (at least 50 particles were scored for each condition). C, D, Purified MRV stock incubated
with PBS (MRV control) or oligomeric Aβ42 (MRV Aβ42) for 2 h, then i.p. injected into P0 BALB/c mice. Thymus was collected 7 dpi and evaluated
for absolute number of CD4+, CD8+, DP (CD4+CD8+ double positive) or DN (CD4−CD8− double negative) C, or MRV DNA load as copies/mL in
the thymus D. ø represents below levels of detection. Data expressed as mean ± SD, one-way ANOVA with Tukey’s post hoc test (two-sided). *P <
0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. No other statistical comparisons are significant unless indicated

After neonatal i.p. infection, we did not detect a difference in Aβ immunoreactivity in the cortex of mock- and
MRV-infected mice (Fig. S1k, l). These findings suggest
that neonatal MRV infection did not facilitate Aβ

deposition when assessed at two timepoints (pre- and
post-plaque).
Extracellular Aβ plaque formation begins at around 8
weeks in 5XFAD mice in the cortex [30]. It may be
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Fig. 3 Peripheral MRV infection in adult 5XFAD mice does not affect Aβ plaque burden. A Schematic of experimental paradigm. B Absolute number
of CD3+, CD4+, or CD8+ T cells in the spleen of 6-months-old 5XFAD mice infected with mock or MRV (i.p.). C Copies/mL of MRV DNA in cortex at 6months-old or 7 dpi in thymus. D, E, Representative images of HJ3.4B staining for pan-Aβ immunoreactivity D and quantification of percent area
coverage in the cortex E. Scale bar: 500 μm. F–I, Protein concentrations of PBS-soluble Aβ40 (f) and Aβ42 (g), or 5 M guanidine-soluble (“insoluble”) Aβ40
H and Aβ42 I in the cortex. J–L, Representative images of Iba1 staining for microglia J and quantification of percent area coverage in cortex K and
hippocampus L. Scale bar: 500 μm. ø represents below levels of detection. Data expressed as mean ± SEM , –, multiple t-tests using Holm-Sidak
method B, one-way ANOVA with Tukey’s post hoc test (two-sided) C. *P < 0.05. No statistical comparisons are significant unless indicated

possible that pre-existing plaques in conjunction with
viral infection are required to trigger downstream neuropathogenesis. We therefore also performed i.p. infections
at 9 weeks, after the onset of plaque formation, and evaluated Aβ plaque load at 3 mpi, at 6 months of age, a
timepoint characterized by high Aβ plaque burden (Fig.
3a). Although we previously observed CD4+ T cell depletion at 10 dpi, we did not observe prolonged CD4+ T cell
depletion in the periphery or significant levels of MRV
DNA in the cortex of 5XFAD mice at 3 mpi (Fig. 3b, c).
Moreover, there was no change in cortical Aβ plaque
pathology between mock- and MRV-infected mice when
assessed using two methodological approaches, histology
and enzyme-linked immunosorbent assay (ELISA) (Fig.

3d–i). Similarly, there was no difference in Iba1+ microglial coverage in the cortex and hippocampus of mockand MRV-infected mice (Fig. 3j–l). These results suggest
that adult MRV infection does not facilitate Aβ progression and formation in a mouse model of amyloidosis.
Taken together, these data suggest that peripheral infection with MRV did not accelerate or increase Aβ formation in 5XFAD mice, despite an acute inflammatory
response in the CNS and periphery.
Adult CNS infection with MRV results in acute
inflammation but does not increase Aβ load

One possible explanation for the discrepancy between
our findings and previous work on the effects of viral
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Fig. 4 CNS MRV infection in adult 5XFAD does not accelerate Aβ formation but induces neuroinflammation. A Schematic of experimental
paradigm. B Copies of MRV ORF69 DNA 72 hpi of mock or MRV, delivered bilaterally into the hippocampus of 6-week-old 5XFAD mice. C–E,
Representative images of HJ3.4B staining for pan-Aβ immunoreactivity (Aβ-IR) with insets depicting intracellular Aβ-IR C and quantification of
percent area coverage in the cortex D or hippocampus E. F Quantification of extracellular Aβ plaque deposits in cortex overlaying hippocampus.
G–H, CNS inflammatory response to MRV in the hippocampus measured by gene transcript changes G and Iba1+ immunostaining for microglia
(H, I). hpi: hours post injection. Scale bar: 500 μm. Data expressed as mean ± SEM, student’s t-test (b, d, e, f, h), and multiple t-tests F. *P < 0.05, **
P < 0.01. ns = not statistically significant. No statistical comparisons are significant unless indicated

pathogens on Aβ deposition could conceivably be differences in the route of infection [5]. One study that demonstrated enhanced Aβ aggregation in 6-week-old mice
after HSV-1 infection was performed using direct, intracranial hippocampal infection [5]. Therefore, we performed a similar experiment in which we injected MRV
(4 × 106 genome copies of virus stock) bilaterally into the
hippocampus and evaluated Aβ load 72 h post infection
(hpi) (Fig. 4a). We used a semi-purified viral stock,
which showed similar infection characteristics compared
to unpurified stocks, to reduce any impact of non-viral
components on Aβ load and inflammation (Fig. S2). We
detected MRV DNA in the hippocampus of all infected
mice (Fig. 4b). However, we detected no change in Aβ
immunoreactivity in the hippocampus and cortex (Fig.
4c–e), or formation of extracellular Aβ plaques (Fig. 4f).
Similar to neonatal, peripheral infections, MRV intracranial infection stimulated an acute, inflammatory response marked by an upregulation in microglial,
astrocytic, and pro-inflammatory cytokine-related gene
transcripts (Fig. 4g). These data were supported by an
increase in Iba1+ microglial coverage in the hippocampus of MRV-infected brains (Fig. 4h, i). There was also

an increase in total tau immunoreactivity in the cortex
(Fig. S3a–c), which was potentially a response to focal
inflammation [52–54]. There was not a statistically significant increase in total tau immunoreactivity in the
hippocampus or phosphorylated tau in the cortex or
hippocampus (Fig. S3e-g). Our findings suggest that
MRV can induce inflammation in the brain after direct
CNS infection, but neither MRV nor inflammation secondary to infection are sufficient to rapidly increase Aβ
deposition in the brain.
HHV-6 abundance is similar between human AD and
control brains

RNAseq data from the Knight-ADRC cohort was available from frozen brain parietal cortex tissue for 381 individuals. Only a subset of the Knight-ADRC cohort was
considered for this study where clinical data for each individual included Clinical Dementia Rating (CDR) score
at the time of death and neuropathological assessment
(Table 1). We performed RNA-seq analysis similar to
previously described studies [36–39], aligning reads to
the human genome followed by alignment of unmatched
reads to 25,799 pathogens, including 118 human viruses
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Table 1 Demographics of RNAseq samples from Knight-ADRC cohort. Abbreviations: SD, standard deviation; APOE4+,
apolipoprotein E4 carriers; CDRe, Clinical Dementia Rating at death; Braak DLB, Braak stages for dementia Lewy body; PMI,
postmortem interval in hours; AD, Alzheimer’s disease; CO, controls; AAO, age at disease onset in years; AOD, Age of death in years

[19]. Identification of HHV-6 transcripts was rare in
non-AD control and AD samples (HHV-6A: 1/31 in
non-AD controls and 2/350 in AD; HHV-6B: 1/31 in
non-AD controls and 3/350 in AD) (Fig. 5a). HHV-7
transcripts were not identified in either the non-AD or
AD samples. Upon arranging individuals based on their
PathSeq scores, we observed no clear distinction of viral
abundance between the individuals with AD vs. the controls (Fig. 5b). The normalized PathSeq score was based
on the number of reads that align with a references
taxon and indicates the amount of evidence that a taxon
is present in a particular individual [44]. Moreover, upon
checking the relationship between viral abundance and
AD classification using the non-parametric Wilcoxon
Rank Sum test, we observed no significant difference for
either HHV-6A (P-value = 0.11) or HHV-6B (P-value =
0.22) between AD and controls groups (Fig. 5a). Therefore, our data, similar to a recent study [14], does not
support an association between human roseolovirus infection and AD in the analysis of this cohort.

Discussion
The relationship between the human roseoloviruses and
AD has been of significant recent interest. While several
studies have reported an association between HHV-6 or
HHV-7 and AD [6, 17–19, 55], others have provided
data that there is not a relationship [14, 20, 56, 57]. Currently, mouse models of human HHV-6 are limited.
MRV is a natural murine pathogen and is highly related
to HHV-6 and HHV-7, sharing genetic, morphologic
and disease homology [26]. Moreover, our studies demonstrate that MRV enters the CNS and replicates in the
cortex. Studying MRV therefore affords an opportunity
to perform in vivo studies to model human roseolovirus
neuropathogenesis, especially its relation to neuropathological features of AD-like disease in mice.
The antimicrobial protection hypothesis of Aβ posits
that pathogens causing persistent or recurrent infections
in the CNS are sequestered by Aβ, triggering a hyperreactive innate immune response that results in Aβ fibrillization and consequently contributes to AD [50]. Indeed,
we found that purified Aβ42 interacted with MRV

particles in vitro and, subsequent to this interaction, disrupted infection in vivo. We therefore evaluated Aβ deposition after MRV infection to test the antimicrobial
hypothesis for MRV infection. Natural infection with
MRV likely occurs through secretions [58], but i.p. infection would similarly require MRV to enter the CNS
from the periphery, which we found did indeed occur
after neonatal infection. However, in our studies, we did
not observe an increase in Aβ after MRV infection of
5XFAD mice. It is important to note that, similar to
other recent studies [5, 59], we focused on expression of
human transgenic Aβ and did not evaluate endogenous
mouse APP expression, which has been suggested to
have antimicrobial properties [4]. Factors such as the
impact of MRV infection on APP expression driven by
the endogenous mouse promoter compared to the Thy1 promoter remain to be explored. We approached investigating the impact of infection in multiple ways, including utilizing two routes of infection (peripheral, i.p.
or direct CNS, intracranial), infecting at various timepoints (pre- or post-Aβ plaque development), as well as
multi-timepoint assessments post-infection (acute or
chronic). None of these scenarios resulted in increased
Aβ load, suggesting that MRV does not facilitate the
progression of Aβ accumulation over time.
Eimer et al. demonstrated that high dose intracranial
HSV-1 infection in 5XFAD mice induced Aβ plaque formation by 72 h in 6-week-old-mice, with colocalization
of Aβ plaques with HSV-1 viral particles [5]. A subsequent study that attempted to repeat these results with
defined HSV-1 strains, albeit with potentially lower
multiplicity of infection, did not observe colocalization
of HSV-1 and Aβ plaques [60]. Neither study quantified
the Aβ plaque load after infection, an important analysis
given the rapid plaque formation reported in the former
study. We therefore performed similar intracranial infections of 6-week-old 5XFAD mice with MRV and did not
observe extracellular Aβ plaque formation. A caveat of
these studies is intracranial injection was not performed
at a later time point when Aβ plaques have begun to accumulate, which conceivably could be further seeded by
a virus. Our studies were limited by the current lack of
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(See figure on previous page.)
Fig. 5 Relationship between viral abundance and AD status. A Comparisons of HHV-6A and -6B viral abundance between AD (N = 350) and nondemented controls (N = 31) in the Knight-ADRC cohort. Diamonds in violin plot: mean of group. Shape of violin plot: distribution of normalized
PathSeq scores across each group. The p-values representing the significance of difference between the viral abundance in AD and controls
groups for HHV-6A and -6B are shown at the top of corresponding violin plots. The p-values were obtained by performing a non-parametric
Wilcoxon Rank Sum test in order to determine if there was any relationship between viral abundance and AD classification. Abbreviations: AD,
Alzheimer Disease; CO, controls; HHV, human herpes virus. B Abundance of HHV-6A and HHV-6B in Knight-ADRC. HHV-6A and HHV-6B normalized
PathSeq scores displayed in an increasing order for all the samples (AD and controls) in the Knight-ADRC cohort. Normalized PathSeq score
based on the number of reads that align with a references taxon and indicates the amount of evidence that a taxon is present in a
particular individual

tools available to evaluate localization of MRV in tissues
such as MRV-specific antibodies. Although we cannot
compare doses between MRV and HSV-1, we cannot
rule out that higher doses of MRV could induce Aβ
formation.
The association between AD and human roseolovirus
has been the focus of numerous multi-omics studies. A
study of multiple cohorts utilizing genomic, transcriptomic and proteomic data reported an association between AD and human roseoloviruses, especially HHV6A and HHV-7 [19]. Furthermore, the data suggested
that certain pathways associated with inflammation and
viral immune response were differentially expressed in
AD patients compared to non-AD controls. Two subsequent studies have called these findings into question.
One study performing a reanalysis of the data with different statistical methods showed no difference [20]. An
additional study of three AD cohorts using RNAseq and
digital droplet PCR analysis did not establish differences
in human roseolovirus detection between AD and control samples [14, 20]. Similar to the study by Allnut,
et al., we did not identify an association between human
roseoloviruses and AD in our RNAseq analysis of the
Knight-ADRC cohort. HHV-6A and HHV-6B were only
detected in a few patients in both the AD and non-AD
control samples. Moreover, given the small number of
positive patients, we could not establish a statistically
significant PathSeq score between the AD and non-AD
groups. Although our data do not rule out a potential
contribution of human roseoloviruses in the pathogenesis of AD, especially at an individual level, it does support recent data suggesting that roseoloviruses are not
associated with AD at the population level.
Although herpesviruses have garnered interest as
causative contributors to development of AD due to
their neurotropism and chronic infections with periodic
reactivation, utilizing -omics analysis from a single time
point does not allow for evaluation of the viral load during, and frequency of reactivation. Moreover, selectively
sampling CNS tissue at times of reactivation is not possible under most circumstances in human subjects. Several recent studies have suggested that treatment with
antivirals for herpesvirus infections was associated with
a decreased risk of dementia later in life compared to

untreated patients [61–64]. In these studies, treatment
generally was given in relatively short intervals considering the lifelong nature of herpesvirus infections, and
many patients were treated with acyclovir, which has
low efficacy against HHV-6 [65–67]. Prospective randomized control trials will likely address the use of
herpes-specific antivirals for AD, although studying the
impact of antiviral on reactivation in mice could provide
a means to test efficacy in vivo. Indeed, a recent study
using thermal stress to serially reactivate HSV-1 in mice
demonstrated that intermittent stress resulted in HSV-1
reactivation, inflammation, and increased Aβ deposition
in the brain [59]. While MRV reactivation has not been
examined in detail, it is possible that MRV also requires
induced reactivation through intermittent stress to promote Aβ accumulation. Additionally, reinfection with
roseoloviruses in general is not well understood, including in the context of AD. Further evaluation of reinfection could provide important information regarding the
role of roseoloviruses in AD. An important consideration for our studies and future studies is that the mechanism of MRV spread within tissue could impact Aβ
accumulation. Human roseolovirus infection is thought
to be largely cell-associated or through exosomes, which
could make them less accessible to extracellular Aβ aggregation [68]. Perhaps higher viral loads resulting in increased extracellular MRV-Aβ interaction is necessary to
increase Aβ plaque formation, which may be why we did
not observe Aβ accumulation in 5XFAD mice that have
an intact immune system.
While MRV infection did not result in increased Aβ,
we determined that MRV interacts with Aβ, and that it
infects the brain and acutely induces neuroinflammation.
Whether MRV has cell-specific tropism is also unknown.
It is possible that Aβ entrapment of viral pathogens facilitated Aβ seeding, but upregulation of diseaseassociated microglia rapidly assisted in the phagocytosis
and removal of Aβ plaques before further seeding and
spreading of Aβ could occur. However, as there were no
differences between viral load in the cortex of WT and
5XFAD mice, if Aβ indeed sequestered MRV, it likely
did not neutralize sufficient viral load to prevent further
replication. Additional research could provide insight
into CNS cell types that are especially vulnerable to
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infection which may result in Aβ-independent toxic effects. Furthermore, it has been suggested that genetic
variation resulting in an altered immune response to
pathogens could contribute to viral load and reactivation
in AD [19, 69]. Our study utilized inbred mouse strains
(5XFAD mice on a B6SJL background) that do not have
immunodeficiency, but it is possible that MRV infection
of mice with defects in genes involved in viral immune
response could cause increased Aβ load due to higher
viral burden during acute infection or reactivation. For
example, miR-155 knockout mice crossed to an APP/
PS1 mouse developed increased Aβ load in the cortex
compared to APP/PS1 controls [19]. miR-155 has been
suggested to be important in controlling herpesvirus latency and is downregulated during lytic HHV-6 replication in NK cells [70, 71]. MRV infection of miR-155
knockout, or other mice with altered viral immune response mice could provide new insight into the relationship between immune control of roseolovirus lytic and
latent infection and AD.
Our findings in this study do not support or refute the
antimicrobial protection hypothesis of Aβ. However, our
results suggest that HHV-6 is not a main contributor for
increased AD risk in humans at a population level. MRV
infections, like human roseolovirus infections, are well
controlled in immunocompetent hosts and do not result
in mortality. Neonatal infection of WT and 5XFAD mice
resulted in similar levels of MRV DNA and RNA in the
cortex 7 dpi, suggesting Aβ has minimal, if any, antiviral
properties towards neutralizing MRV after infection in
5XFAD mice. Although some markers of inflammation
trended higher in the 5XFAD mice compared to WT littermates, these differences were not statistically significant. Despite this, a major finding in the current study
was that MRV actively infects the brain and stimulates
an inflammatory response, even after peripheral infection. Moreover, we found that Aβ interacts with MRV
in vitro and, subsequent to this interaction, inhibits
in vivo infection. In addition to further studies of the relationship between MRV and AD-like phenotypes in
mice, MRV could be studied in other diseases characterized by CNS inflammation. Human roseoloviruses have
been associated with several other inflammatory and
autoimmune CNS diseases, including viral encephalitis,
multiple sclerosis, and Rasmussen encephalitis [72–74].
Given the limitations of current mouse models of roseolovirus infection, MRV could be highly useful for performing deliberate, controlled studies to uncover the
mechanistic role of a roseolovirus in CNS disease.

Conclusion
Human roseoloviruses, HHV-6 and HHV-7 have recently been investigated for their role in AD, although
studies in humans have provided controversial results.
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MRV is highly related to the human roseoloviruses,
allowing for evaluation of the role of a natural murine
roseolovirus in neuroinflammation and Aβ accumulation. Although Aβ interacted with MRV and disrupted
infection, we found that MRV did not induce increased
Aβ load after peripheral or direct CNS infection. However, we demonstrated that MRV actively infects the
brain and induces neuroinflammation, providing a suitable in vivo system for further studies of the impact of
roseolovirus infection of the brain.
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Additional file 1: Supplementary Fig. 1. Peripheral, neonatal MRV
infection in 5XFAD mice does not accelerate Aβ plaque burden. A,
Schematic of experimental paradigm (6 mpi). B, C, Percent of CD4+ and
CD8+ T cells in plasma 10 dpi (B) or 6 mpi (C). D, E, HJ3.4B+
immunostaining for Aβ plaque load in the cortex. F–I, Staining and
quantification for Tau5+ total tau (F, G) and AT8+ phosphorylated tau in
the cortex (H, I). J, Schematic of experimental paradigm (6 wpi). K, L,
Percent area HJ3.4B+ Aβ immunoreactivity (Aβ - IR) in cortex. Dpi: days
post infection. Mpi: months post infection. Wpi: weeks post infection. ptau: phosphorylated tau. Scale bar: 500 μm. Data expressed as mean ±
SEM, student’s t-test (B, C, E, G, J, M). No statistical comparisons are significant unless indicated.
Additional file 2: Supplementary Fig. 2. Comparisons between MRV
purified and unpurified stocks. A – C, Stocks were created from in vivo
passage and collection of 7 day post neonatal infection thymi and were
used directly (MRV Stock) or semi-purified (MRV Purified). BALB/c mice
were mock- or MRV-infected with MRV Stock or MRV Purified via i.p. injection on P0 then were evaluated by flow cytometry for percent CD4+ cells
per total CD3+ cells from the spleen at 7dpi (A) or weight at 7dpi (B). C,
Copies of MRV DNA per mL of stock were evaluated by qPCR.
Additional file 3: Supplementary Fig. 3. Effects of acute,
intrahippocampal MRV infection on tau pathology. A, Schematic of
experimental paradigm. B – G, Staining and quantification for Tau5+ total
tau (B, C, D) and AT8+ phosphorylated tau in the cortex (E, F, G). p-tau:
phosphorylated tau. Scale bar: 500 μm. Data expressed as mean ± SD, student’s t-test. *P < 0.05. ns = not statistically significant. No statistical comparisons are significant unless indicated.
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